AFM
IMNP

Anson Funds Management’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Anson Funds Management’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-41,935
Closed -$110K – 66
2017
Q2 		$110K Buy
+41,935
New +$113K 0.03% 44

Other funds holding IMNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Anson Funds Management's IMNP Position: Q3 2017 in Review

Anson Funds Management sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2017, closing a stake of 41,935 shares — an estimated $110K sold.

Anson Funds Management first reported a position in IMNP in Q2 2017 and held it in 1 quarter. The position peaked at $110K in Q2 2017. 12 funds tracked by Wall St. Rank hold IMNP as of Q3 2017.

  • Anson Funds Management reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
  • Anson Funds Management sold 41,935 Immune Pharmaceuticals Inc. shares in Q3 2017, an estimated $110K.
  • Anson Funds Management first reported a position in Immune Pharmaceuticals Inc. in Q2 2017 and held it in 1 quarter.
  • Anson Funds Management's Immune Pharmaceuticals Inc. position peaked at $110K in Q2 2017.
  • 12 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2017.

Based on Anson Funds Management's 13F filing for Q3 2017, filed 14 Nov 2017.